Valneva SE priced its previously flagged and fully underwritten €40 million (US$53.3 million) rights issue at €2.65 per share, a steep discount on the company's prevailing share price of €4.61 immediately prior to the final pricing decision. Read More

LONDON – Scientists have teased out a molecular mechanism that allows synapses to respond as quickly or as slowly as required for all neurological functions ranging from simple movements to cognitive function. Read More

LONDON – "I really hope to create a building where as you walk round the corridors, at the coffee machine and in the cafeteria, that you hear people talking science, that science becomes the language of the place." Read More

When Trevor Baglin, a hematologist at Addenbrooke's Hospital at Cambridge University had a head injury patient with a much-better-than-expected outcome, he did something unusual. He got very curious. Read More

LONDON – South Korean biotech Kael-Gemvax is planning further investment and new clinical trials of GV1001, despite the cancer vaccine failing to meet the primary endpoint in a 1,062-patient UK Phase III trial that reported earlier this month. Read More

LONDON – The ongoing row over clinical trials data transparency in Europe has polarized yet further, with a threat from scientist campaigners to publish results from previously confidential documents if companies do not pledge to make results of unpublished studies available in the next year, by submitting them to peer-reviewed journals. Read More

SHANGHAI, China – A licensing agreement may help troubled Israeli firm Biolinerx Ltd. get a toehold in China with its hepatitis C virus (HCV) treatment BL-8030. Read More

• Immunogenes AG, of Zug, Switzerland, and Corvinius Kockazati Tokealap-kezelo Zrt, of Budapest, Hungary, formed a joint venture to fund the establishment for a scientific facility to develop and produce monoclonal and polyclonal antibodies and genetically modified animals in Godollo, Hungary. Read More